['breast neoplasms']
['ipatasertib', 'paclitaxel', 'placebo']

        Inclusion Criteria:

          -  Histologically documented triple-negative adenocarcinoma of the breast that is
             inoperable locally advanced or metastatic and is not amenable to resection with
             curative intent

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor
             specimen, required prior to randomization

          -  Measurable disease, according to the RECIST v1.1

          -  Adequate hematologic and organ function within 14 days before the first study
             treatment

          -  For female participants of childbearing potential, agreement (by both participant and
             partner) to use an effective form of contraception for the duration of the study and
             for 6 months after last dose of study treatment

        Exclusion Criteria:

          -  Any previous therapy, including chemotherapy or hormonal or targeted therapy, for
             inoperable locally advanced or metastatic triple-negative adenocarcinoma of the
             breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy
             and/or radiation treatment for locally advanced triple negative adenocarcinoma,
             provided all treatments were completed greater than or equal to (>/=) 6 months prior
             to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with
             curative intent

          -  Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1

          -  Known Human Epidermal Growth Factor Receptor 2 (HER2) positive, erythrocyte receptor
             (ER) positive, or progesterone receptor (PR) positive breast cancer

          -  Previous therapy with Akt, PI3K, and/or mTOR inhibitors

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
             prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during
             the course of the study

          -  Known presence of the brain or spinal cord metastasis, as determined by computed
             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or
             prior radiographic assessments
      